U.S. FDA Offers Up Revised PDUFA Date In June For Takeda’s Alogliptin
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA has set a new action date of June 26, 2009 for Takeda's dipeptidyl peptidase IV inhibitor alogliptin, after missing the original user fee deadline of Oct. 27, the company announced Dec. 24